CER's Place In Drug Development Is A Work In Progress, FDA Says
Executive Summary
FDA has a lot of work to do before it can determine how comparative effectiveness research might play into its evaluation of new drug approvals or labeling changes, Chief Scientist and Acting Deputy Commissioner for Science and Public Health Jesse Goodman told a conference sponsored by the Friends of Cancer Research June 18